Kenvue (NYSE:KVUE) Sets New 52-Week Low - What's Next?

Key Points

• Kenvue's stock price hit a new 52-week low at $15.94, with significant trading volume of over 16 million shares.
• Analysts have mixed perspectives on Kenvue, with price targets ranging from $22.00 to $25.00, while the stock currently holds a consensus rating of "Hold."
• Kenvue recently increased its quarterly dividend to $0.2075 per share, representing a yield of 5.2%, despite a high payout ratio of 112.16%.

Kenvue Inc. (NYSE:KVUE - Get Free Report)'s stock price reached a new 52-week low on Wednesday . The stock traded as low as $15.94 and last traded at $15.97, with a volume of 16476947 shares trading hands. The stock had previously closed at $16.23.

Analysts Set New Price Targets

KVUE has been the subject of several research analyst reports. Rothschild Redb upgraded shares of Kenvue from a "hold" rating to a "strong-buy" rating in a research note on Friday, September 26th. Redburn Partners set a $22.00 price target on shares of Kenvue in a research note on Friday, September 26th. Royal Bank Of Canada decreased their price target on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. UBS Group decreased their price target on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. Finally, Citigroup restated a "neutral" rating on shares of Kenvue in a research note on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $22.73.

Kenvue Stock Down 2.2%

The stock's fifty day moving average is $20.12 and its two-hundred day moving average is $21.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $30.47 billion, a PE ratio of 21.45, a P/E/G ratio of 2.35 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm's quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 5.2%. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue's payout ratio is currently 112.16%.

Institutional Investors Weigh In On Kenvue

Institutional investors have recently added to or reduced their stakes in the business. Pittenger & Anderson Inc. purchased a new stake in Kenvue during the first quarter valued at about $30,000. Trust Co. of Vermont lifted its holdings in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock valued at $33,000 after purchasing an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC purchased a new stake in Kenvue during the first quarter valued at about $36,000. Truvestments Capital LLC purchased a new stake in Kenvue during the first quarter valued at about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd lifted its holdings in Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after purchasing an additional 1,287 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.